Antiestrogens: Mechanisms of action and resistance in breast cancer

Breast Cancer Research and Treatment

Volumn 44, Issue 1, 1997, Pages 23-38

  Katzenellenbogen, Benita S ^a,b   Montano, Monica M ^a   Ekena, Kirk ^a   Herman, Mary E ^a   McInerney, Eileen M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Antiestrogen resistance; Antiestrogens; Breast cancer; Endocrine therapy; Estrogen receptor; Hormone sensitivity; Resistance; Tamoxifen

Indexed keywords

ANTIESTROGEN; CYCLIC AMP; ESTROGEN RECEPTOR; GROWTH FACTOR; LIGAND; TAMOXIFEN;

BONE; BREAST CANCER; CARDIOVASCULAR SYSTEM; CELL INTERACTION; DRUG EFFICACY; DRUG METABOLISM; FEMALE; GENE MUTATION; HORMONE SENSITIVITY; HUMAN; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; UTERUS; BREAST TUMOR; DRUG RESISTANCE; GENETICS; METABOLISM;

BREAST NEOPLASMS; DRUG RESISTANCE; ESTROGEN ANTAGONISTS; FEMALE; HUMANS;

EID: 0031136676     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005835428423     Document Type: Review

References (96)

1. Katzenellenbogen BS, Fang H, Ince BA, Pakdel F, Reese JC, Wooge CH, Wrenn CK: Estrogen receptors: Ligand discrimination and antiestrogen action. Breast Cancer Res Treat 27:17-26, 1993
2. Katzenellenbogen BS, Montano M, Le Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N: Antiestrogens: Mechanisms and actions in target cells. J Steroid Biochem Molec Biol 53:387-393, 1995
3. Osborne CK, Elledge RM, Fuqua SAW: Estrogen receptors in breast cancer therapy. Sci Am Sci Med 3:32-41, 1996
4. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11: 578-610, 1990
5. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
6. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549, 1996
7. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Bur J Cancer 30A: 1714-1721, 1994
8. Katzenellenbogen BS: Estrogen receptors: Bioactivities and interactions with cell signaling pathways. Biol Reprod 54:287-293, 1996
9. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10:119-131, 1996
10. Sarrel PM, Lufkin EG, Oursler MJ, Keefe D: Estrogen actions in arteries, bone and brain. Sci Am Sci Med 1:44-53, 1994
11. Kneifel MA, Katzenellenbogen BS: Comparative effects of estrogen and antiestrogen on plasma renin substrate levels and hepatic estrogen receptors in the rat. Endocrinology 108:545-552, 1981
12. Toney TW, Katzenellenbogen BS: Antiestrogen action in the medial basal hypothalamus and pituitary of immature female rats: insights concerning relationships among estrogen, dopamine and prolactin. Endocrinology 119:2661-2669, 1986
13. Wakeling AE, Bowler J: Biology and mode of action of pure antiestrogens. J Steroid Biochem 30:141-147, 1988
14. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873, 1991
15. Nique F, Van de Velde P, Bremaud J, Hardy M, Philibert D, Teutsch G: 11β-amidoalkoxyphenyl estradiols, a new series of pure antiestrogens. J Steroid Biochem Molec Biol 50:21-29, 1994
16. Nicholson RI, Gee JMW, Francis AB, Manning DL, Wakeling AE, Katzenellenbogen BS: Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells. Endocrine Related Cancer 2:115-121, 1995
17. Wakeling AE: The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25:1-9, 1993
18. Sato M, Rippy, MK, Bryant HU: Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10:905-912, 1996
19. Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273:1222-1225, 1996
20. Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818, 1990
21. Montano MM, Muller V, Trobaugh A, Katzenellenbogen BS: The carboxy terminal F-domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814-825, 1995
22. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30, 1994
23. Kraus WL, McInerney EM, Katzenellenbogen BS: Ligand-dependent, transcriptionally productive association of the amino- and carboxyl- terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci USA 92:12314-12318, 1995
24. Tsai MJ, O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486, 1994
25. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
26. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995
27. Cho H, Katzenellenbogen BS: Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Molec Endocrinol 7: 441-452, 1993.
28. Cho H, Aronica SM, Katzenellenbogen BS: Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic AMP, estradiol, IGF-1 and serum factors. Endocrinology 134:658-664, 1994
29. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach KS: Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 89:4658-4662, 1992
30. Gronemeyer H: Transcriptional regulation by estrogen and progesterone receptors. Annu Rev Genet 25:89-123, 1991
31. Montano MM, Müller V, Trobaugh A, Katzenellenbogen BS: The carboxy-terminal F domain of the human estrogen receptor: Role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814-825, 1995
32. Read LD, Katzenellenbogen BS: Characterization and regulation of estrogen and progesterone receptors in breast cancer. In: Dickson RB, Lippman ME (eds) Genes, Oncogenes and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Kluwer Academic Publishers, Boston, 1991, pp 277-299
33. Dickson RB, Lippman ME: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8:29-43, 1987
34. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428, 1987
35. Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB: Induction of transforming growth factor β by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol (CCT) 14(Suppl 2):S15-S20, 1991
36. Vignon F, Bouton MM, Rochefort H: Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146:1502-1508, 1987
37. Katzenellenbogen BS, Norman MJ: Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/IGF-I, serum and estrogen. Endocrinology 126:891-898, 1990
38. Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing turnover. Proc Natl Acad Sci USA 89:4037-4041, 1992
39. Montano MM, Ekena KE, Krueger KD, Keller AL, Katzenellenbogen BS: Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10:230-242, 1996
40. Haran EF, Maratzek AF, Goldberg I, Horwitz A, Degani H: Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54:5511-5514, 1994
41. McCloskey DE, Armstrong DK, Jackisch C, Davidson NE: Programmed cell death in human breast cancer cells. Recent Prog Horm Res 51:493-508, 1996
42. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, Tronick SR, Page DL, King MC, Holt JT: BRCA1 is secreted and exhibits properties of a granin. Nature Genetics 12:303-308, 1996
43. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930, 1996
44. Mosselman S, Polman J, Dijkema R: ERβ: identification and characterization of a novel human estrogen receptor. FEBS Letters 392:49-53, 1996
45. Pakdel F, Katzenellenbogen BS: Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 267:3429-3437, 1992
46. Wrenn CK, Katzenellenbogen BS: Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem 268: 24089-24098, 1993
47. Katzenellenbogen BS, Bhardwaj B, Fang H, Ince BA, Pakdel F, Reese JC, Schodin DJ, Wrenn CK: Hormone binding and transcription activation by estrogen receptors: Analyses using mammalian and yeast systems. J Steroid Biochem Molec Biol 47:39-48, 1993
48. Fawell SE, Lees JA, White R, Parker MG: Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60:953-962, 1990
49. Danielian PS, White R, Hoare SA, Fawell SF, Parker MG: Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7:232-240, 1993
50. Reese JC, Katzenellenbogen BS: Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor: Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. J Biol Chem 267:9868-9873, 1992
51. Ekena KE, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS: Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding. J Biol Chem 271: 20053-20059, 1996
52. Ekena K, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS: Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens. J Biol Chem 272: 5069-5075, 1997
53. Allan GF, Leng XH, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O'Malley BW: Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513-19520 1992
54. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669, 1995
55. Fujimoto N, Katzenellenbogen BS: Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen-selectivity and promoter-dependence. Mol Endocrinol 8:296-304, 1994
56. Oñate SA, Tsai SY, Tsai M-J, O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354-1357, 1995
57. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455-1458, 1994
58. Cavaillés V, Dauvois S, Danielian PS, Parker MG: Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 91: 10009-10013, 1994
59. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS: Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10:1388-1398, 1996
60. McInerney EM, Katzenellenbogen BS: Different regions in activation function-1 of the human estrogen receptor required for antiestrogen-dependent and estradiol-dependent transcription activation. J Biol Chem 271:24172-24178, 1996
61. McInerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS: Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA 93:10069-10073, 1996
62. Katzenellenbogen BS: Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83:1434-1435, 1991
63. Touchette N: Tamoxifen resistance in breast cancer. J NIH Research 4:67-72, 1992
64. McGuire WL, Chamness GC, Fuqua SAW: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571-1577, 1991
65. Miksicek RJ, Lei Y, Wang Y: Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Res Treat 26:163-174, 1993
66. Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52:483-486, 1992
67. Garcia T, Sanchez M, Cox JL, Shaw PA, Ross JBA, Lehrer S, Schachter B: Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nucleic Acids Res 17:8364-8368, 1989
68. Murphy LC, Dotzlaw H: Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 3:687-693, 1989
69. McGuire WL, Chamness GC, Fuqua SAW: The importance of normal and abnormal oestrogen receptor in breast cancer. Cancer Surveys 14:31-40, 1992
70. Fuqua SAW, Chamness GC, McGuire WL: Estrogen receptor mutations in breast cancer. J Cell Biochem 51:135-139, 1993
71. Castles CG, Fuqua SAW: Alterations within the estrogen receptor in breast cancer. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone Dependent Cancer. Marcel Dekker, New York, 1996, pp 81-105
72. Karnik PS, Kulkarni S, Liu X, Budd GT, Bukowski RM: Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54:349-353, 1994
73. Herman ME, Katzenellenbogen BS: Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Molec Biol 59:121-134, 1996
74. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477-1482, 1991
75. Scott GK, Kushner P, Vigne J-L, Benz CC: Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest 88:700-706, 1991
76. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92:4206-4210, 1995
77. Wolf DM, Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31:129-138, 1994
78. Pakdel F, Reese JC, Katzenellenbogen BS: Identification of charged residues in an N-terminal portion of the hormone binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol Endocrinol 7:1408-1417, 1993
79. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355-4360, 1987
80. Clarke R, Brünner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Soonmyoung P, Lippman ME, Dickson RB: Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86:3649-3653, 1989
81. Jiang S, Wolf DM, Yingling JM, Chang C, Jordan VC: An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90:77-86, 1992
82. Vassilomanolakis ME, Tsoussis S, Kandylis K, Hajichristou E, Efredmidis AP: Rechallenge by tamoxifen in metastatic breast cancer: Prospective study of different dose levels. Breast Dis 4:129-134, 1991
83. Stoll BA: Intermittent antiestrogen therapy in advanced breast cancer. Cancer Treat Rep 67:98, 1983
84. Stoll BA: Rechallenging breast cancer with tamoxifen therapy. Clin Oncol 9:347-351, 1983
85. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS: Phosphorylation of the human estrogen receptor: Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458-4466, 1994
86. Minton JP, Wisenbaugh T, Matthews RH: Elevated cyclic AMP levels in human breast-cancer tissue. J Natl Cancer Inst 53:283, 1974
87. Cohen LA, Chan P: Intracellular cAMP levels in normal rat mammary gland and adenocarcinoma: In vivo vs. in vitro. Life Sci 16:107-115, 1974
88. Miller WR, Elton RA, Dixon JM, Chetty U, Watson DMA: Cyclic AMP binding proteins and prognosis in breast cancer. Br J Cancer 61:263-266, 1990
89. Miller WR, Watson DMA, Jack W, Chetty U, Elton RA: Tumour cyclic AMP binding proteins: An independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat 26:89-94, 1993
90. Kvinnsland S, Ekanger R, Døskeland SO, Thorsen T: Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer. Breast Cancer Res Treat 3:67-72, 1983
91. Watson DMA, Hawkins RA, Bundred NJ, Stewart HJ, Miller WR: Tumour cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer. Br J Cancer 56:141-142, 1987
92. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988
93. Osborne CK: Tamoxifen metabolism as a mechanism for resistance. Endocrine-Related Cancer 2:53-58, 1995
94. Howell A, DeFriend D, Robertson J, Blamey R, Walton P: Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345:29-30, 1995
95. Hu XF, Veroni M, De Luise M, Wakeling A, Sutherland R, Watts CKW, Zalcberg JR: Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 55:873-876, 1993
96. Wakeling A: Physiological effects of pure antiestrogens. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone Dependent Cancer. Marcel Dekker, New York, 1996, pp 107-115